Filterable News List

Hong Kong, Hong Kong - Cre8 Enterprise Limited (Nasdaq: CRE), a Hong Kong-based integrated financial printing service provider, announced that its wholly owned subsidiary, Cre8 Incorporation Limited, has completed the acquisition of 100 percent of the issued shares of Lingxpert Language Services Limited.

The acquisition, valued at US$800,000 in cash, was finalized under a share purchase agreement. LingXpert is a Hong Kong-based firm providing translation services since 2011. The transaction is designed to strengthen Cre8's capacity to support clients on both IPO and non-IPO engagements, minimize operational bottlenecks, and reduce overhead costs through resource sharing.

Acquisition Highlights

• Acquired 100 percent of Lingxpert Language Services Limited.
• Purchase price of US$800,000 paid in full in cash.
• Expands in-house translation capacity and shortens turnaround times.
• Aims to optimize capital expenditures and scale operations effectively.

Traverse City, Michigan, USA - Hagerty, Inc. (NYSE: HGTY), an automotive lifestyle brand and specialty vehicle insurer, reported its financial results for the third quarter ended September 30, 2026, showcasing strong underlying operational performance and record member growth.

During the first nine months of 2026, the company added a record 402,000 new members, pushing total policies in force up 18% year-over-year to 1.9 million. Written premium grew 18% to $1,099 million for the year-to-date period, while earned premium increased 42% to $757 million. Driven by this momentum and the successful transition to the Markel Fronting Arrangement, Hagerty increased its full-year 2026 profit outlook, projecting net income between $48 million and $60 million and adjusted EBITDA between $305 million and $315 million.

Financial Highlights

• Third quarter 2026 written premium increased 16% year-over-year to $386 million.
• Third quarter 2026 net income reached $36 million, compared to $46 million in the prior year period.
• Adjusted EBITDA for the third quarter increased 64% year-over-year to $97 million.
• Hagerty Re combined ratio improved to 79.7% in the third quarter compared to 89.6% in the prior year period.

PETAH TIKVA, Israel, Nov. 03, 2026 - TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB), a developer of combined heat and power systems based on multifuel microturbines, announced the completion of the first assembly of its proprietary TR2000 system. The unit is a 20 kilowatt system designed for defense applications as well as residential buildings and other civilian projects.Following…

… Read on — Pro Members

Taiyuan, China, Nov. 03, 2026 -- Rising Dragon Acquisition Corp. (Nasdaq: RDAC, RDACU, RDACR), a special purpose acquisition company, announced that it and HZJL Cayman Limited have mutually agreed, effective as of October 30, 2026, to terminate their previously announced Agreement and Plan of Merger.

The termination was approved by the boards of directors of both Rising Dragon and HZJL. Under the terms of the Termination Agreement, no party is required to pay a termination fee, and all parties have agreed to mutually release each other from claims relating to the merger agreement and its contemplated transactions, subject to certain exceptions.

Transaction Details

• Effective Date: October 30, 2026
• Termination Fee: None required by any party
• Future Plans: Rising Dragon will continue to pursue an initial business combination

Rising Dragon intends to continue seeking an appropriate target business to consummate an initial business combination within the timeframe permitted under its governing documents. Additional information regarding the termination will be filed with the U.S. Securities and Exchange Commission in a Current Report on Form 8-K.

NEW YORK and SALEM, Ore. -- Churchill Capital Corp XI (Nasdaq: CCXI) announced that its shareholders have approved the business combination with Agility Robotics, Inc., a humanoid robotics and physical AI company.At a special meeting, shareholders voted in favor of the transaction, which received support from more than 84% of the votes cast. The gross…

… Read on — Pro Members

SAN MIGUEL DE ALLENDE, Mexico - November 2, 2026 - Sinda Ltd. (NYSE: SIND, BMV: SIND) announced its third quarter 2026 operational and financial results, highlighting continued drilling success and notable progress toward the Caracol exploration decline.

During the third quarter, Sinda launched earthworks for underground development, moving approximately 6,500 cubic meters of material. The company also advanced Phase 2 drilling by completing roughly 31,150 meters and achieved its highest-grade drill intercept to date at Caracol, alongside maintaining a strong safety record with a TRIFR of 0.00.

Operational Highlights

• Launched earthworks in September, preparing the exploration decline portal and Waste Rock Storage Facility.
• Advanced Phase 2 drilling with 18 rigs, completing 31,150 meters focused on resource conversion and exploration.
• Achieved a record drill intercept at Caracol of 3.05 meters grading 12,494 g/t AgEq.
• Maintained strong safety performance with over 501,480 work hours without lost-time incidents.

Corporate Highlights

• Added to the VanEck Junior Gold Miners ETF (GDXJ) in September 2026.
• Listed on the International Quotation System (SIC) of the Mexican Stock Exchange.
• Appointed Alberto Zinser to the Board of Directors.

As of September 30, 2026, Sinda reported cash and cash equivalents totaling $305.6 million, leaving the company fully funded to execute its ongoing exploration program and underground decline development.

NEW YORK, NY and ITASKA, IL, November 2, 2026 - tZERO Group, Inc., a financial technology company powering tokenized financial markets through regulated Infrastructure-as-a-Service solutions, and FG Imperii Acquisition Corp. (Nasdaq: FGII), a publicly traded special purpose acquisition company, announced that they have entered into a definitive business combination agreement.

The proposed transaction values tZERO at a pre-money equity valuation of $350 million, including up to $25 million to be realized upon the achievement of specified milestones. Existing tZERO shareholders are expected to roll 100 percent of their equity interests into the combined company. Following the closing, the combined company common stock is expected to trade on NYSE American under the ticker symbol TZRO.

The combined company may receive up to approximately $231 million of cash held in FG Imperii trust account, subject to redemptions and transaction expenses. An affiliate of FG Imperii has also provided additional capital to tZERO previously announced funding round and entered into a term sheet for a forward purchase agreement.

Key Highlights

• Diversified regulated infrastructure across the asset lifecycle including tokenization, transfer agent, brokerage, trading, custody, clearing, and settlement capabilities.
• Established regulatory foundation operating through multiple regulated entities.
• More than a decade of digital market experience since 2014.
• Infrastructure-as-a-Service growth model offering API and white label solutions for B2B and B2B2C partners.

Kuala Lumpur, Malaysia - Bradbury Capital Inc. (NASDAQ: BBCI and BBCIW) announced an adjustment to the exercise price and the redemption trigger price of its outstanding public warrants following the completion of a USD 5 million PIPE financing.The adjustments were triggered in accordance with Section 4.6 of the Warrant Agreement following a business combination and…

… Read on — Pro Members

BOSTON, USA - Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage therapeutics company, announced its financial results for the third quarter of 2026, alongside significant corporate and clinical advancements. The company highlighted positive clinical milestones for its neuropsychiatric drug candidates, GlyphAllo and GlyphAgo, and reported a robust cash position expected to fund operations into 2029.

Daphne Zohar, Co-Founder and Chief Executive Officer, emphasized the company's progress, stating, "Over the last few months, Seaport met two key clinical milestones - we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial." She noted that Seaport is now advancing two Phase 2 programs and is well-capitalized to pursue its mission of developing better medicines for mental illness.

Key Clinical Progress

GlyphAllo Program for Major Depressive Disorder (MDD):

• Positive Phase 1 Driving Simulation Data: Seaport announced positive topline data from a Phase 1 trial in healthy volunteers, demonstrating that evening dosing of GlyphAllo (375 mg) did not impair next-morning driving performance compared to placebo. A 250 mg dose also showed no impairment. The drug was well-tolerated.
• Phase 2b BUOY-1 Trial On Track: Enrollment is progressing as planned for the global, randomized, double-blind, placebo-controlled Phase 2b BUOY-1 trial in MDD patients. Topline data from this potentially registration-enabling trial are anticipated in the first half of 2027.

GlyphAgo Program for Generalized Anxiety Disorder (GAD):

• Phase 2a Proof-of-Pharmacology Trial Initiated: The first patient has been dosed in a Phase 2a trial evaluating GlyphAgo's effects on sleep and anxiety severity in GAD patients with sleep disturbance. Topline data are expected in early 2028.
• Planned Phase 2/3 Trial: Seaport plans to initiate a global, randomized, double-blind, placebo-controlled, potentially registration-enabling Phase 2/3 trial for GlyphAgo in GAD in the first half of 2027, with topline data expected by year-end 2028.
• Pharmacokinetic Data Presented: Detailed Phase 1 pharmacokinetic data showed dose-dependent increases in agomelatine exposure, no food effect, and no accumulation over seven days, reinforcing significantly increased bioavailability and reduced PK variability compared to unmodified agomelatine.

Preclinical Programs:

• Glyph2BLSD (SPT-348): The development of this non-hallucinogenic neuroplastogen for neuropsychiatric and headache disorders is on track, with first-in-human-enabling studies expected to be completed by year-end 2027.

Third Quarter 2026 Financial Highlights

Financial Overview:

• Cash Position: As of September 30, 2026, cash, cash equivalents, and investments totaled 403.8 million USD. This is expected to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
• R&D Expenses: Research and development expenses increased to 23.9 million USD for Q3 2026, up from 20.5 million USD in Q3 2025, primarily due to the advancement of the GlyphAllo Phase 2b BUOY-1 trial.
• G&A Expenses: General and administrative expenses rose to 6.5 million USD for Q3 2026, compared to 5.0 million USD in Q3 2025, mainly due to increased costs associated with operating as a public company.
• Net Loss: The net loss for Q3 2026 was 26.4 million USD, compared to a net loss of 22.5 million USD for Q3 2025.

Piscataway, New Jersey, United States -- BHAV Acquisition Corp II announced the closing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, trading on the Nasdaq Global Market under the ticker symbol BHAIU.Concurrently with the closing of the offering, the company completed a private placement of 225,000 private…

… Read on — Pro Members